Longeveron's ELPIS II Phase 2b trial of Laromestrocel, a cell therapy delivered during Stage II palliative surgery in 40 infants with hypoplastic left heart syndrome, did not meet its primary endpoint of change in right ventricular ejection fraction at 12 months. A prespecified secondary endpoint reached statistical significance, with one major adverse cardiac event in the treatment arm versus eight under standard of care (P=0.043), alongside no treatment-related serious adverse events. The divergence between a structural imaging measure and clinical event rates illustrates how regenerative interventions may act through mechanisms that conventional surrogate endpoints fail to capture.
Key Points
- Primary endpoint of right ventricular ejection fraction change was not met
- Major adverse cardiac events: one treated versus eight standard-of-care (P=0.043)
- No treatment-related serious adverse events through twelve months
Longevity Analysis
Ejection fraction measures pump geometry; it does not capture the inflammatory signaling, vascular remodeling and tissue repair processes that determine whether a compromised heart deteriorates or holds. A therapy that leaves the imaging metric unchanged while reducing hospitalizations, transplants and deaths points to the limits of single-surrogate assessment across cardiac regenerative medicine broadly. For anyone evaluating interventions intended to preserve organ function over decades, the lesson is that the marker chosen defines the answer obtained — and clinically meaningful benefit often registers first in event rates, not in structural measurements.
Original published by LT Wire.